Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
-
Published:2023-12
Issue:6
Volume:84
Page:571-578
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Grünwald ViktorORCID, Ivanyi Philipp, Zschäbitz Stefanie, Wirth Manfred, Staib Peter, Schostak Martin, Dargatz Philip, Müller Lothar, Metz Michael, Bergmann Lothar, Steiner Thomas, Welslau Martin, Lorch Anja, Rafiyan Reza, Hellmis Eva, Darr Cristopher, Schütt Philipp, Meiler Johannes, Kretz Thomas, Loidl Wolfgang, Flörcken Anne, Mänz Martin, Hinke Axel, Hartmann Arndt, Grüllich Carsten
Funder
Bristol-Myers Squibb Co
Reference28 articles.
1. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Powles;Ann Oncol,2020 2. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013 3. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial;Motzer;Cancer,2020 4. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial;Cella;Lancet Oncol,2016 5. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma;Grünwald;Eur Urol,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|